(MIST) – Corporate News
-
Milestone Pharmaceuticals (MIST) Announces Etripamil Data Demonstrating Patients’ Ability to Self-Manage Recurring PSVT, Presented at ACC
-
Milestone Pharmaceuticals Inc. (MIST) Resubmits NDA for Etripamil for Treatment in Paroxysmal Supraventricular Tachycardia
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Back to MIST Stock Lookup